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Exosomes are endosomal origin membrane-enclosed small vesicles (30–100 nm)
that contain various molecular constituents including proteins, lipids, mRNAs and
microRNAs. Accumulating studies demonstrated that exosomes initiated and regulated
neuroinflammation, modified neurogenic niches and neurogenesis, and were even of
potential significance in treating some neurological diseases. These tiny extracellular
vesicles (EVs) can derive from some kinds of multipotent cells such as mesenchymal
stem cells (MSCs) that have been confirmed to be a potentially promising therapy
for traumatic brain injury (TBI) in experimental models and in preclinical studies.
Nevertheless, subsequent studies demonstrated that the predominant mechanisms
of MSCs’s contributions to brain tissue repairment and functional recovery after TBI
were not the cell replacement effects but likely the secretion-based paracrine effects
produced by EVs such as MSCs-derived exosomes. These nanosized exosomes
derived from MSCs cannot proliferate, are easier to preserve and transfer and have lower
immunogenicity, compared with transplanted exogenous MSCs. These reports revealed
that MSCs-derived exosomes might promise to be a new and valuable therapeutic
strategy for TBI than MSCs themselves. However, the concrete mechanisms involved
in the positive effects induced by MSCs-derived exosomes in TBI are still ambiguous.
In this review, we intend to explore the potential effects of MSCs-derived exosomes on
neuroinflammation and neurogenesis in TBI and, especially, on therapy.
Keywords: exosomes, mesenchymal stem cells (MSCs), traumatic brain injury (TBI), neuroinflammation,
neurogenic niches, neurogenesis, therapy
INTRODUCTION
Exosomes are the smallest endocytic origin membrane-bound nanovesicles which participate
in the complex intercellular communication system (Lamichhane et al., 2015; Merino-Gonzalez
et al., 2016). They are released from various cell types under normal or pathological conditions,
influencing the activity of recipient cells by carrying active signals. Exosomes contain not only
cellular proteins and lipids, but also messenger RNAs (mRNAs) and microRNAs (miRNAs) from
the host cell (Barteneva et al., 2013). The potential clinical values of exosomes can be attributed
to their characteristics such as: their surface markers and molecular cargoes that can be taken
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as potential diagnostic biomarkers for some diseases (Muller,
2012; Dorayappan et al., 2016; Escudero et al., 2016), their low
immunogenicity and long half-life in circulation and their ability
to cross the brain-blood barrier (BBB) (Sun et al., 2010; Alvarez-
Erviti et al., 2011; Kalani et al., 2014), and their potential roles
as mediators of the regenerative responses (Lai et al., 2010;
Xin et al., 2012). As for the relationships between exosomes
and neurological diseases, the cell-based therapy such as stem
cell therapy should be mentioned first. At present, stem cell
therapy has been proposed to be a promising therapeutic option
for several neurological disorders including Stroke, Parkinson’s
disease, Amyotrophic Lateral Sclerosis and Huntington’s disease
(Yoo et al., 2013). As the secretomes of the stem cells appear
to be of greater benefit on tissue regeneration and repair
than the stem cells themselves (Teixeira et al., 2013), the
extracellular components such as stem cell-derived exosomes
that are responsible for their therapeutic benefits have begun
to be noticed. One of the most popular stem cell-derived
exosomes which are widely applied in neurological diseases
researches are the mesenchymal stem cells (MSCs)-derived
exosomes. It has been systematically elaborated in several latest
reviews that MSCs-derived exosomes play an important role in
neuroinflammation, neurogenic niches and neurogenesis, and
therapeutic strategy of neurological diseases (Gupta and Pulliam,
2014; Batiz et al., 2015; Luarte et al., 2016; Marote et al.,
2016).
Traumatic brain injury (TBI) is a set of secondary pathological
and/or functional alteration within brain due to a sudden external
force, a major cause of death and longterm disability worldwide
(Menon et al., 2010; Chauhan, 2014). Until recently, no clinical
trials have identified effective pharmacologic treatments in TBI
(Narayan et al., 2002; Xiong et al., 2013; Skolnick et al.,
2014; Wright et al., 2014). In the past decade, lots of studies
demonstrated that MSCs had promised to be an effective therapy
for brain injury not only in experimental models of TBI (Lu
et al., 2001; Chopp and Li, 2002; Mahmood et al., 2004a,b; Li and
Chopp, 2009; Nichols et al., 2013), but also potentially in clinical
practices (Zhang et al., 2008; Cox et al., 2011). However, the
dominating mechanisms of MSCs’s participation in brain tissue
repairment and functional restoration after TBI are likely related
to their secretion-based paracrine effects rather than the cell
replacement effects (Chopp and Li, 2002; Li and Chopp, 2009).
One sort of the MSCs secretion-based paracrines are MSCs-
derived exosomes that characterized by without proliferation, less
immunogenic and easier to store and deliver than MSCs (Lai
et al., 2011). Newly studies indicate that MSCs-derived exosomes
can improve functional recovery, rescue pattern separation and
spatial learning impairments, promote neurovascular remodeling
(neurogenesis and angiogenesis) and reduce neuroinflammation
in animal models after TBI (Zhang et al., 2015; Kim et al.,
2016; Zhang Y. et al., 2016). Although the above reports
reveal that MSCs-derived exosomes may promise to be a better
therapy for TBI than MSCs, the concrete mechanisms and
molecular constituents that involved are still not clear. In order
to address this issue preliminarily, we proposed this review to
introduce the foremost new progresses in paracrine mechanisms
of MSCs-derived exosomes and explore their potential effects
on neuroinflammation, neurogenesis, and especially, on therapy
of TBI.
EXOSOMES
The extracellular vesicles (EVs) have been recently identified
as a novel type of mediators in intercellular communication.
Although EVs were initially regarded as membrane-enclosed
vesicles secreted just by outward shedding or budding of the
cells’ plasma membrane (PM), it is recently known that various
types of EVs with different formation approaches coexist in
the extracellular milieu including different tissues and biological
fluids (Colombo et al., 2014). Some types are originated from
shedding of the PM, while others are secreted by exocytosis
after fusion of the lumen that is so-called multivesicular bodies
(MVBs) or multivesicular endosomes with the PM (Colombo
et al., 2014). Based on these various intracellular origins
and biogenesis formation approaches, EVs may have different
compositions, functions and types (Kowal et al., 2014). Exosomes
are thought to be one subtype of the most thoroughly studied
EVs which are formed inward MVBs through the endolysosomal
approach and are released from fusion of MVBs with the
PM (Kalani et al., 2014). They are membrane-enclosed vesicles
and contain various molecular constituents including cell type
characteristic combination of lipids, proteins, coding and non-
coding RNAs (Lener et al., 2015). In recent years, a lot of
researches about exosomes with the purpose to explore the
primary mechanisms of their formation and secretion and their
roles in intercellular communication have been conducted and
made great progresses. The main characteristics of exosomes
were summarized in Table 1.
Biogenesis of Exosomes
Exosomes are 30–100 nm endocytic origin membrane
vesicles secreted by various types of cells and mediate diverse
functions in intercellular communication (Lener et al., 2015;
TABLE 1 | The characteristics of exosomes.
Characteristics Description
Definition The smallest endocytic origin membrane-bound
nanovesicles
Size 30–100 nm
Cellular origin Various cell types under normal or pathological
conditions
Formation mechanisms Forming MVBs by the ESCRT dependent and
ESCRT independent approaches
Main contents Proteins, lipids, mRNAs and miRNAs from the host
cells
Membrane markers CD9, CD63, CD81, CD82
Biogenesis functions Mediate diverse functions in intercellular
communication
Main advantages Low immunogenicity, long half-life in circulation and
ability to cross the BBB
MVBs, multivesicular bodies; ESCRT, Endosomal Sorting Complex Required for
Transport; mRNAs, messenger RNAs; miRNAs, micro RNAs; BBB, brain-blood
barrier.
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Willms et al., 2016). As a well characterized population of EVs,
exosomes can be distinguished by the combination of their size
and origin. They originate in the endocytic approaches which are
involved in the trafficking of several proteins that are internalized
and can either recycle back to the PM or get sorted to degradation
(Gould and Lippincott-Schwartz, 2009; Klumperman and
Raposo, 2014). In these approaches, early endosomes develop
into late endosomes, and they experience an inward budding
procedure of their membrane and form the intraluminal vesicles
(ILVs) with diameter ranging approximately from 30 to 100 nm
during the developing process. The late endosomes, often termed
MVBs because of containing ILVs, may either fuse with the
lysosome and lead their contents to be degraded, or fuse with the
PM that permits the ILVs to be discharged into the extracellular
environment, these EVs are then defined as exosomes (van Niel
et al., 2006). The formation of ILVs and exosomes is a modulated
procedure that includes arranging endosomal membrane into
distinctive domains which are extremely rich in special sets of
membrane proteins. One set of proteins include CD81, CD82,
CD63, and CD9 which are intensively assembled on the exosome
membranes and act as marker proteins for these vesicles. The
other set of proteins are the components of the Endosomal
Sorting Complex Required for Transport (ESCRT) equipment
that are approximately constituted by thirty proteins which
form four complexes (ESCRT-0, ESCRT-I, ESCRT-II, ESCRT-III)
(Hanson and Cashikar, 2012). As for the mechanism of the
formation of MVBs and ILVs, there are two main pathways
that have been described: the ESCRT dependent and ESCRT
independent mechanisms. The ESCRT dependent mechanism
is the best-described pathway that sequesters ubiquitinated
membrane proteins into an endosomal microdomain and
induces an invagination that generates ILVs formation harboring
this cargo. ESCRT-0 complex acts a crucial role in determining
the outcome of membrane proteins enriched on endosomes, it
identifies and secludes ubiquitinated transmembrane proteins
on the endosomal membrane and further separates them into
microdomains and combines the ESCRT-I complex. ESCRT-I
complex, the first described ESCRT complex, is essential for
sorting cargo into the MVBs and efficiently creating ILVs. It
recruits ESCRT-II complex after binding ESCRT-0 complex in
turn, and then both complexes initiate membrane deformation
into buds with sorted cargo that allow cytosolic proteins and
RNAs (mRNAs and miRNAs) to get into the forming vesicles.
ESCRT-II connects ESCRT-I and ESCRT-III and works in the
canonical ESCRT pathway. ESCRT-III differs from the other
ESCRT complexes in that its components are soluble monomeric
proteins that are related to each other and polymerize into
filaments when recruited to the membrane, and activated by
interaction with upstream pathway components. The ESCRT-
II complex first recruits ESCRT-III subunits inside nascent
vesicles and then together with the ATPase VPS4 provokes
the membrane cleavage process required to free ILVs, during
which ESCRT subunits and ubiquitin molecules are secreted into
the cytosol for further recycling (Hanson and Cashikar, 2012).
The exosomes biogenesis also occurs potentially via ESCRT-
independent mechanisms which have been recently proposed as
alternative pathways for the formation and assembling special
cargo into exosomes, involving a lipid-driven mechanism
(Trajkovic et al., 2008) and a sphingosine 1-phosphate receptor
dependent mechanism (Kajimoto et al., 2013). In addition,
another alternative mechanism that only needs the enlisting of
the ESCRT-III subgroup CHMP4 can also be a pathway for the
formation and sorting of exosomes by interacting an ESCRT-III
binding protein ALIX with proteins comprising of late-domain
motif LYPXnL like the GPCR Par1 or syntenin (Sette et al., 2010;
Baietti et al., 2012; Hurley and Odorizzi, 2012).
Contents of Exosomes
Exosomes are lipid-bilayer vesicles that contain cellular specific
lipids, proteins, coding and non-coding RNAs (Lener et al., 2015).
The proteins contained in most exosomes include membrane
proteins of the tetraspanin family (CD81, CD82, CD63, and
CD9), proteins associated with MVB biogenesis (Alix, TSG101)
that participates in the ESCRT, heat shock proteins (HCP/HSP
70 and 90) and proteins required for membrane transport and
fusion (Rab GTPases, annexins, and flotillins) (Ohno et al.,
2013; Raposo and Stoorvogel, 2013). In addition, cytoskeletal
proteins (actin, syntenin, and moesin), signal transduction
proteins (kinase proteins) and metabolic enzymes (GAPDH,
LDHA, PGK1, aldolase, and PKM) are carried by exosomes
as well (Chaput and Thery, 2011). The lipids compositions
contained in exosomes usually exist on the exosomal membrane
where there are numerous lipid-rafts consisting of cholesterol,
ceramide, sphingomyelin and glycerophospholipids with long
and saturated fatty-acyl chains (Thery et al., 2006; Kowal et al.,
2014). The coding and non-coding RNAs contained in exosomes
generally refer to mRNAs and miRNAs. The mRNAs enclosed in
exosomes may play more of a regulatory rather than a functional
role (Batagov and Kurochkin, 2013), though they can be readily
translated to proteins by the recipient cells (Valadi et al., 2007).
The miRNAs are the most widely described ncRNAs of exosomes
that target the 3
′
untranslated region (UTR) of specific mRNAs
to inhibit their translation in most cases. As a consequence of
this, miRNAs can modify the phenotype and/or the physiology
of the recipient cell, modulating cellular processes as relevant
as proliferation, differentiation and survival among others
(Cocucci and Meldolesi, 2015). Although all exosomes contain
the constitutive array of proteins, lipids and RNAs as illustrated
above, their contents vary in accordance with the cellular origin
and the physiological or pathological condition of the cell and its
extracellular environment. Therefore, the contents of exosomes
not only relate to their different cellular functions, but also act
as indicators of their cellular sources. Furthermore, the distinct
exosomes that enclose different proteins and RNA compositions
determine their various subpopulations and, therefore, yield
different effects on recipient cells.
MSCs-DERIVED EXOSOMES
Mesenchymal stem cells-derived exosomes are one of the
most popular stem cell-derived exosomes that are widely
applied in neurological diseases researches. MSCs are a sort
of adult multipotent cells owning the self-renew capacity and
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differentiation potential which have been investigated in cell
replacement strategies with the purpose to repair damaged
adult mesenchymal or ectodermal tissues such as neural tissue
(Pittenger et al., 1999; Donega et al., 2014; Takeda and Xu, 2015;
Bagher et al., 2016). However, the primary mechanism of MSCs
mediated regeneration effect is not its cellular engraftment and
differentiation but a secretome-based paracrine activity. One of
the bioactive factors secreted from MSCs is the MSCs-derived
exosomes which were firstly isolated and characterized from
human ESC-derived MSCs conditioned medium in Lai et al.
(2010). Compared to other cell types, the MSC is the most
prolific exosome producer that can produce large amounts of
exosomes which are not different from the exosomes derived
from other sources in terms of morphological features, isolation
and storage conditions (Yeo et al., 2013). As the constituents
of exosomes are dependent on their cellular origin (Raposo
and Stoorvogel, 2013), the contents of MSCs-derived exosomes
have their own characteristics. In addition to the common
surface markers of exosomes, MSCs-derived exosomes involve
special membrane binding proteins such as CD73, CD44, and
CD29 (Lai et al., 2012). The protein components of MSCs-
derived exosomes also changed when these cells were obtained
from different MSCs cultured media. RNAs such as mRNA
and miRNAs are encapsulated in MSCs-derived exosomes as
well. Most of the studies have demonstrated that MSCs-derived
exosomes contained various miRNAs which participated in the
cell–cell communication and altered the fate of recipient cells
(Koh et al., 2010; Xin et al., 2012, 2013; Katakowski et al.,
2013; Lee et al., 2013; Ono et al., 2014). It has been widely
accepted that the exosome secretion is an efficient adaptive
mechanism that environmental challenges can influence the
composition, biogenesis, and secretion of exosomes. The MSCs-
derived exosomes profile can be modified by pretreatment as
well. One research indicated that the amount of miR-133b in
MSCs and their released exosomes significantly elevated when
MSCs were in vitro exposed to brain tissue extracted from
rats suffered from middle cerebral artery occlusion (MCAo),
compared to MSCs which were exposed to normal brain tissue
extracts (Xin et al., 2012). Another research also indicated that
the miR-22 level in MSCs-derived exosomes increased after
ischemic preconditioning (Feng et al., 2014). Above researches
indicate that the MSC and its environment can deliver feedback
information to each other through MSCs-derived exosomes. That
is to say, the environment of MSC will modify the contents of
its secreted exosomes which can affect and modify the tissue
environment consequently.
In recent years, a plenty of researches have been conducted
to explore the potential therapeutic values of MSCs-derived
exosomes from different MSCs sources. The most common
MSCs sources are bone marrow (BM) (Zhu et al., 2012;
Zhang Y. et al., 2016), embryonic stem cell (ESC) (Lai
et al., 2010; Zhang et al., 2014; Zhang S. et al., 2016) and
umbilical cord (UC) (Fang et al., 2016; Zhang B. et al.,
2016), and others include adipose (AD) (Hu et al., 2016),
induced pluripotent stem cell (iPSC) (Qi et al., 2016), menstrual
(Men) (Lopez-Verrilli et al., 2016) and synovial (Guo et al.,
2016). Accordingly, exosomes derived from different sources
MSCs might have different isolation, identification and delivery
methods. Ultracentrifugation is the most common method used
to isolate exosomes by which the exosomes are precipitated
by centrifugation at ≥100,000 × g for at least 1 h. Other
methods include high-performance liquid chromatography
(HPLC), ultrafiltration and ExoQuick-TC. Common methods
used to identify exosomes include Electron microscopy for the
morphology identification, Flowcytometry and Western blotting
for the membrane marker (CD9, CD63, and CD81) identification.
The exosomes can be quantified by measuring the total protein
concentration using BCA protein assay kit, ELISA kit and
TABLE 2 | The different isolation, identification and delivery methods of various origin MSC derived exosomes.
Origin Isolation method Identify method Delivery method Reference
hBM-MSC Ultracentrifugation
(100,000 × g
1 h)/ultrafiltration/ExoQuick-TC
Western blotting Subcutaneous/intravenous
injection
Zhu et al., 2012;
Zhang Y. et al., 2016
hESC-MSC Ultracentrifugation
(100,000 × g
1 h)/ultrafiltration/HPLC
Flowcytometry,
Western blotting
Intravenous/intra-
articular/subcutaneous
injection
Lai et al., 2010; Zhang
et al., 2014; Zhang S.
et al., 2016
hUC-MSC Ultracentrifugation
(120,000 × g 70 min)/
(100,000 × g 1 h)
Electron microscopy,
Western blotting
Subcutaneous
injection, in vitro
coculture
Fang et al., 2016;
Zhang B. et al., 2016
hAD-MSC Ultracentrifugation
(120,000 × g 90 min)
Electron microscopy,
Western blotting
Intravenous injection Hu et al., 2016
hiPSC-MSC Ultracentrifugation
(100,000 × g 2 h)
Western blotting Intravenous injection Qi et al., 2016
hMen-MSC Ultracentrifugation
(100,000 × g 70 min)
Electron microscopy,
Flowcytometry,
Western blotting
In vitro coculture Lopez-Verrilli et al.,
2016
hS-MSC Ultracentrifugation
(100,000 × g 1 h)
Western blotting Intravenous injection Guo et al., 2016
MSC, mesenchymal stem cell; hBM, human bone marrow; hESC, human embryonic stem cells; hUC, human umbilical cords; hAD, human adipose; hiPSC, human
induced pluripotent stem cell; hMen, human menstrual; hS, human synovial; HPLC, high-performance liquid chromatography.
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other kinds of kit. The concrete amounts of MSCs-derived
exosomes that were obtained and used in the researches had
great differences according to the MSCs sources, isolation and
quantification methods and experiment protocols. Methods used
to delivery exosomes include intravenous/subcutaneous/intra-
articular injection in vivo and coculture in vitro. Though many
previous studies demonstrated various methods for the isolation,
identification and delivery of MSCs-derived exosomes, there
is no standard consensus until now. The different isolation,
identification and delivery methods of various human origin
MSCs derived exosomes were summarized in Table 2.
MSCs-DERIVED EXOSOMES AND TBI
Previous studies indicated that MSCs promised to be an
effective therapy for brain injury in experimental models and
clinical practices of TBI (Lu et al., 2001; Chopp and Li, 2002;
Mahmood et al., 2004a,b; Zhang et al., 2008; Li and Chopp,
2009; Cox et al., 2011; Nichols et al., 2013). However, it
has been documented recently that the major mechanisms of
MSCs participating in brain remodeling and functional recovery
after TBI are not the cell replacement effects but likely the
paracrine effects of secretion-based factors such as MSCs-derived
exosomes (Chopp and Li, 2002; Li and Chopp, 2009; Lai et al.,
2011). Excitingly, newly studies demonstrate that MSCs-derived
exosomes can reduce neuroinflammation, promote neurogenesis
and angiogenesis, rescue pattern separation and spatial learning
impairments, and improve functional recovery after TBI in
animal models (Zhang et al., 2015; Kim et al., 2016; Zhang Y.
et al., 2016). These reports indicate that MSCs-derived exosomes
may promise to be a better therapy for TBI than MSCs.
In the above paragraphs, we have reviewed the biogenesis
and contents of exosomes and MSCs-derived exosomes. And
we will go on in the next paragraphs to further discuss the
roles of MSCs-derived exosomes in the neuroinflammation,
neurogenesis and therapy of TBI, the probable mechanisms
and molecular constituents that might be involved in, and
some preliminary suggestions related to future researches. The
probable mechanisms of the effects produced by MSCs-derived
exosomes on TBI were illustrated in Figure 1.
MSCs-Derived Exosomes and the
Neuroinflammation of TBI
Neuroinflammation plays an important role in the pathogenesis
of TBI and occurs during its whole primary and secondary stages
(Lozano et al., 2015). It seems to be responsible for not only the
detrimental effects contributing to primary insult and secondary
injury but also the beneficial effects facilitating tissue repair
(Woodcock and Morganti-Kossmann, 2013). The development
of neuroinflammation occurring within the brain following TBI
involves a complex process of cumulative alterations. Instantly
after the TBI insult, multiple types of quiescent glial cells
become rapidly activated via a “reactive gliosis” procedure which
includes initiating microglia activation and continuing astrocytic
activation via the generation and secretion of inflammatory
mediators which further work on surrounding neurons and glial
cells in turn (Chiu et al., 2016). This brain inflammation reaction
in TBI is featured by glial cells activation, leukocytes recruitment,
and generation and release of inflammatory mediators such as
chemokines and cytokines (Morganti-Kossmann et al., 2001).
These inflammatory mediators not only influence surrounding
glial cells and neurons but also recruit peripheral immune cells
such as neutrophils, macrophages and lymphocytes into brain.
Though the above cellular endogenous inflammatory responses
triggered by the primary insult are aiming to repair the damaged
tissue, the excessive production of pro-inflammatory cytokines
usually become a significant driving force for the pathological
progression of TBI. The excessive neuroinflammation not only
initiates a primary damage phase which involves diffuse axonal
injury, contusion and laceration, intracranial hemorrhage and
brain swelling that invariably leads to instant cell death (LaPlaca
et al., 2007; Cheng et al., 2012; Greig et al., 2014), but also induces
an extended secondary phase that involves cascades of biological
processes aiming to potentially restore the cellular homeostasis of
the impaired brain tissue which is not particularly well controlled
and often will result in exacerbation of the primary injury,
progressive neurodegeneration and delayed cell death (Kabadi
and Faden, 2014; Lozano et al., 2015). Herein, how to alleviate
the acute neuroinflammation following an initial TBI insult and
further beneficially establish new therapies for TBI is a hot
research topic.
Recently, two studies have demonstrated that systemic
administration of cell-free exosomes generated by human MSCs
(hMSCs) with treatment initiated 24 h post injury in a rat model
of TBI significantly reduces the neuroinflammation (Zhang et al.,
2015; Zhang Y. et al., 2016). In these two studies, activation
of GFAP + astrocytes and CD68 + microglia/macrophages was
significantly suppressed by exosomes compared to the liposome
treatment control (Zhang et al., 2015; Zhang Y. et al., 2016).
As the activated astrocytes and microglia play an important
role in the initiation and progression of neuroinflammation
following TBI by releasing inflammatory mediators, suppressing
them by MSCs-derived exosomes can bring an anti-inflammatory
effect which is just like that of MSC therapy in TBI animal
models (Zhang et al., 2013). These studies indicate that MSCs-
derived exosomes might have the potential to be a new novel
strategy to treat neuroinflammation of TBI for their advantages
including nanosize, low immunogenicity, ability to cross the BBB,
capacity to efficiently transport a series of biological molecules
and interact with plenty of targeted cells. Although above studies
indicate that MSCs-derived exosomes have advantages and
potential to be a novel treating strategy for neuroinflammation
of TBI, the concrete cellular and molecular mechanism is still
unclear. As the miRNAs involved in exosomes play a key role in
modifying the phenotype and/or the physiology and modulating
the cellular processes of the recipient cell (Cocucci and Meldolesi,
2015), they might be research targets in the future. In addition,
previous studies have demonstrated that MSCs-derived exosomes
can induce increased levels of anti-inflammatory cytokines and
decreased levels of pro-inflammatory cytokines (Zhang et al.,
2014), inhibit macrophage activation by suppressing Toll-like
receptor signaling (Phinney et al., 2015) and inhibit hypoxic
inflammation by suppressing pro-proliferative pathways such
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FIGURE 1 | Mesenchymal stem cells (MSCs)-derived exosomes reduce neuroinflammation by suppressing the activation of astrocytes and microglia
and promote neurogenesis possibly by targeting the neurogenic niche, both which contribute to nervous tissue repair and functional recovery after
TBI. MSC, mesenchymal stem cell; TBI, traumatic brain injury; ER, endoplasmic reticulum; GC, Golgi complex; MVBs, multivesicular bodies; BBB, brain-blood
barrier; NSC, neural stem cell.
as STAT3 phosphorylation (Lee et al., 2012). These studies
might provide some references and enlightenments for future
researches about the molecular mechanisms and signal pathways
of the reducing neuroinflammation effect in TBI conducted
by MSCs-derived exosomes. What is more, the advantages of
MSCs-derived exosomes may make them to be a potentially
ideal drug delivery vehicle to treat neuroinflammation of TBI.
The idea that exosomes can be taken as a tool to deliver
therapeutic agents to treat inflammatory conditions was first
demonstrated by Sun et al. (2010). The study showed that
exosomes could carry and transmit curcumin which in turn
enhanced their anti-inflammatory effects including increased
stability and bioavailability of the complex and improved survival
rate in lipopolysaccharide (LPS)-induced septicemia (Sun et al.,
2010). Subsequently, one study clearly indicates that anti-
inflammatory agents like curcumin or JSI124 can be effectively
delivered to the brain by exosomes without observable side effects
and alleviate LPS-induced brain inflammation in mice (Zhuang
et al., 2011).
MSCs-Derived Exosomes and the
Neurogenesis of TBI
Following TBI, the primary injury initiatively induces irreversible
brain damage and the secondary injury profoundly affects the
process of the injury and clinical prognosis. There is no effective
treatment for TBI up to now, making exploring new strategies
be an urgent need. Recently, the research on neurogenesis is
developing and neurogenesis turns to be a hopeful strategy for
the repairment and regeneration in the injured brain after TBI
based on the finding that neural stem cells (NSCs) are proven
to exist in the adult brain and are capable of proliferating and
generating functional neurons after brain damage. It was believed
that neurogenesis could not be continued in the adult brain until
latest studies indicate that some areas of the adult brain contain
NSCs and retain the ability to generate neurons and glial cells,
especially the subventricular zone (SVZ) and dentate gyrus (DG)
of the hippocampus (Lois and Alvarez-Buylla, 1993; Gage et al.,
1998). The extent of adult neurogenesis can be influenced by
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many factors including those related to TBI. One recent review
concludes that neurogenesis is enhanced following TBI and
plays an important role in the spontaneous cognitive function
recovery after brain injury, and strengthening or regulating
this endogenic cellular reaction might be a hopeful direction
for researchers to explore new therapeutic strategies for brain
repairment and regeneration following brain injury (Sun, 2016).
This review provides plenty of strategies such as manipulating
transcriptional regulators, supplementing various types of growth
factors and acting intervention on pharmacological pathways
targeting diverse aspects of the endogenous neurogenic responses
that influence adult neurogenesis following TBI (Sun, 2016). In
addition, several latest studies indicated that MSCs effectively
promoted neurogenesis in experimental models of TBI (Lu et al.,
2001; Chopp and Li, 2002; Mahmood et al., 2004a,b; Li and
Chopp, 2009; Nichols et al., 2013). However, the predominant
mechanisms by which MSCs participate in neurogenesis after
TBI are not their cell replacement effects but likely their
secretion-based paracrine effects (Chopp and Li, 2002; Li and
Chopp, 2009). MSCs-derived exosomes are one kind of the
MSCs secretion-based paracrines. Newly studies demonstrated
that MSCs-derived exosomes promoted neurogenesis in animal
models of TBI (Zhang et al., 2015; Kim et al., 2016; Zhang Y.
et al., 2016). In these studies, MSCs-derived exosomes treatment
significantly increased the number of newborn neurons (double
staining for BrdU and NeuN) detected in the granule layer of the
DG compared to the liposome controls. However, the concrete
cellular and molecular mechanism of this neurogenic process is
still unclear.
At present, most of the researchers who concentrate on the
study about neurogenesis of TBI spare their efforts to explore new
strategy to enhance cell proliferation, survival of new neurons
in the neurogenic niche harboring active adult neurogenesis. So,
the relationship between exosomes and neurogenic niches needs
to be discussed before we investigate the role of MSCs-derived
exosomes in the neurogenesis process of TBI. Neurogenic niche
mainly exists in two areas of the brain: the subgranular zone
(SGZ) of the DG in the hippocampus and the SVZ of the lateral
ventricles (LV). It is a unique and specialized microenvironment
which is composed of a variety of cells including glial cells, NSC-
neuron lineage cells and vascular cells. Therefore, an efficient
and well-regulated cell-to-cell communication in the adult
neurogenic niches acts a crucial role in the actional regulation of
plasticity and homeostasis in the neurogenesis process. Previous
studies have made important progress to investigate the cellular
components in the adult neurogenic niches and to explore the
potential mechanisms by which they separately or cooperatively
contribute to modulate adult neurogenesis (Aimone et al., 2014;
Bjornsson et al., 2015; Migaud et al., 2016). Recently, a novel
type of intercellular messengers “exosomes” have been identified.
Exosomes seem to be a distinct intercellular communication
medium for they are involved in the transferring of proteins,
lipids, mRNAs and miRNAs between cells and therefore have
the ability to modify the function of target cells (Cocucci and
Meldolesi, 2015). Although the physiological and pathological
roles of exosomes in the adult neurogenic niches remain virtually
unexplored currently, the concept that exosomes have the
potential to be a primary component available for regulating the
functions of adult neurogenic niches is supported by more and
more indirect evidences as follows. First, most of the cells in
central nervous system (CNS) including NSCs and these cells
that make up and modulate the neurogenic niche can release
and/or be targets of exosomes. Second, some biological molecules
generated and released by niche cells have been verified to
exist in exosomes in physiological or pathological circumstances.
Third, exosomes can serve as messengers between neural cells,
communicators between blood and CNS and modulators of
several stem cell niches (Batiz et al., 2015). Based on these
findings, the neurogenic niche might be a research target for
the exploration of the mechanisms of promoting neurogenesis
in TBI conducted by MSCs-derived exosomes in the near future.
For example, we can explore the possible molecular components
of specific exosome populations in the neurogenic niche by
using proper TBI animal models with which the exosomes can
be labeled through molecular biology techniques and can be
subsequently validated in health control and TBI with the use of
a panel of biomarkers.
In addition, it is well known that several steps of adult
neurogenesis are mediated by various miRNAs, but the definite
targeting cells and mechanisms through which miRNAs are
transmitted to targeting cells in the neurogenic niche are
actually unknown. As several miRNAs including miR-let7b,
miR-9, miR-124, miR-125b, and miR-128 that involved in
the neurogenic/angiogenic process are contained in exosomes
secreted by neurogenic niche cells (Zhao et al., 2009, 2010;
Pogue et al., 2010; Huang et al., 2013; Cernilogar et al., 2015;
Santos et al., 2016; Ye et al., 2016), and the miRNAs contained
in exosomes play key roles in modifying the phenotype and/or
the physiology and in modulating the cellular processes of
the recipient cells (Cocucci and Meldolesi, 2015), they can be
research points as well. One encouraging outcome was obtained
in a middle cerebral artery occlusion model, in which the authors
have presented that the level of miR-133b in MSCs significantly
elevated when they were exposed to ischemic cerebral extracts,
and the miR-133b can be transmitted to neurons and astrocytes
via exosomes and further promotes neurite outgrowth and
brain function recovery (Xin et al., 2012, 2013). This proof-
of-concept study not only demonstrates that MSCs interact
with neurons and astrocytes and modulate neurite outgrowth
by transmitting miRNAs (miR-133b) via exosomes for the
first time, but also helps to partially explain the mechanisms
of MSCs’ contribution to neurological recovery through the
identification of MSCs-derived exosomes as transporters that
transfer miR-133b to neurons and astrocytes after stroke. MSCs-
derived exosomes delivery functional miRNAs such as miR-133b
which promotes neurite outgrowth might show benefit in other
neurological disorders such as TBI as well. In addition, other
researches that focused on non-disease models in vitro also
demonstrated that MSCs-derived exosomes had the potential
to assist neuron differentiation by delivering miRNAs. One
of these researches reported that miR-124 and miR-145 can
be delivered to astrocytes and NPCs through the contact
independent and exosome-dependent procedure that changes
the gene expression of recipient neural cells (Lee et al., 2014).
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These studies might provide some methodology references and
enlightenments for the exploration of the mechanisms of the
promoting neurogenesis effects conducted by MSCs-derived
exosomes in TBI.
MSCs-Derived Exosomes and the
Therapy of TBI
Traumatic brain injury is a leading cause of death and longterm
disability such as behavioral, cognitive and motor deficits
worldwide. At present, there are mainly two therapeutic strategies
to treat TBI, one is a neuroprotective treatment that targets the
injured brain with a focus on reducing or preventing secondary
injury and neural cell death and reducing the lesion size, the
other one is a neurorestorative treatment aiming to improve
neurological recovery via acting on the whole CNS to promote
neurovascular remodeling including angiogenesis, neurogenesis,
oligodendrogenesis and dendrite or axon outgrowth (Xiong
et al., 2013). For a long time, the major efforts of treatment
for TBI were the developments of neuroprotective agents and
more than 30 clinical trials for potential treatment of TBI
have been initiated during the past 3 decades, but almost
all Phase II/III TBI clinical trials have failed (Janowitz and
Menon, 2010; Loane and Faden, 2010). These reports indicate
that no effective treatments currently exist that can improve
neurological outcome after TBI and exploring new therapeutic
approaches to improve functional recovery after TBI is an urgent
need.
Until a decade ago, some researches demonstrated that
the limited ability to exhibit structural and functional
plasticity of brain after injury may prove to be significantly
related to functional recovery (Chopp et al., 2008; Hall and
Traystman, 2009; Xiong et al., 2013). Later, subsequent
preclinical studies indicated that restorative treatments targeting
multiple parenchymal cells including cerebral endothelial cells,
NSCs and oligodendrocyte progenitor cells enhanced TBI-
induced angiogenesis, neurogenesis, oligodendrogenesis and
axonal sprouting respectively and further collectively improved
neurological function after TBI (Xiong et al., 2010a,b). Recently,
cell therapies using NPCs are promising for the treatment of
brain injury (Jain, 2009). However, ethical considerations and
other scientific problems restricted the clinical use of fetal tissues
or ESCs. Then, researchers find that MSCs can be taken as a
feasible source of stem cells for the cell replacement treatment
as they are mesoderm-derived cells which mainly exist in UC
blood, adult BM, peripheral blood and other organs and can
differentiate into neuron cells (Greco and Rameshwar, 2007; Ho
et al., 2008; Kassem and Abdallah, 2008). In the past decade,
accumulating studies demonstrated that MSCs had promised to
be an effective therapy for brain injury not only in experimental
models of TBI (Lu et al., 2001; Chopp and Li, 2002; Mahmood
et al., 2004a,b; Li and Chopp, 2009; Nichols et al., 2013), but
also potentially in clinical practices (Zhang et al., 2008; Cox
et al., 2011). While the predominant mechanisms by which
MSCs participate in brain remodeling and functional recovery
after TBI are likely related to their secretion-based paracrine
effects rather than a cell replacement effect (Chopp and Li, 2002;
Li and Chopp, 2009). MSCs-derived exosomes are one sort of
the MSCs secretion-based paracrines characterized by without
proliferation, easier preservation and transportation and less
immunogenicity compared to MSCs (Lai et al., 2011). The diverse
advantages of exosomes such as their bi-lipid membranes can
keep their biological active constituents being stable which allows
an easier storage and a longer half-life and shelf-life in patients,
and their ability to cross the BBB and reach the brain parenchyma
may make the transformation of MSC therapy from a cell-based
one to a cell-free exosome-based one (Lai et al., 2013). What is
more, the complex protein and genetic cargos of exosomes which
have various biochemical potentials to participate in diverse
cellular and biochemical processes can significantly contribute
to the treatment of complicated diseases such as TBI. Some
researchers even pointed out that the exosome might become a
novel weapon for the treatment of TBI according to its nanosize,
easy administration, ability to across the BBB, potential as a
drug delivery tool and many other advantages (Alvarez-Erviti
et al., 2011; Braccioli et al., 2014). Excitingly, latest studies
demonstrated that intravenous administration of MSCs-derived
exosomes significantly improved functional recovery, rescued
pattern separation and spatial learning impairments, promoted
neurovascular remodeling (angiogenesis and neurogenesis) and
reduced neuroinflammation in TBI animal models (Zhang et al.,
2015; Kim et al., 2016; Zhang Y. et al., 2016). Above studies
indicate that MSCs-derived exosomes provide a potentially
novel cell-free therapy for TBI. As for the mechanisms of the
therapeutic effects of MSC-derived exosomes in TBI, though
Zhang Y. et al. (2016) pointed out that the improved brain
function recovery after treating TBI with exosomes derived from
hMSCs had significant correlation with increased neurogenesis
and angiogenesis and reduced neuroinflammation, the implicited
cellular and molecular components and mechanisms needed to
be explored in future studies.
In addition, as exosomes contain various miRNAs which play
a key role in modifying the phenotype and/or the physiology and
modulating the cellular processes of the recipient cell (Cocucci
and Meldolesi, 2015), and miRNAs such as miR-21 could be
potential therapeutic targets for interventions after TBI (Ge
et al., 2014; Sandhir et al., 2014), the combination of miRNAs
and MSC-derived exosomes might be a novel approach for the
treatment of TBI. That is, MSCs-derived exosomes that carry and
transfer their cargo such as miRNAs to parenchymal cells may
mediate brain plasticity and improve functional recovery after
TBI. Our conception might be partly supported by the studies
which demonstrated that miR-133b, increased in MSCs exposed
to ischemic cerebral extracts, was transferred to neurons and
astrocytes via exosomes and promoted neurite outgrowth and
brain function recovery in a middle cerebral artery occlusion
animal model (Xin et al., 2012, 2013). Another development
direction of the MSCs-derived exosomes treatment in TBI is
their potential to act as a ‘ideal drug delivery vehicle’ on account
of their desirable characteristics including low immunogenicity,
capacity to efficiently transfer a variety of biological molecules
and interact with a plenty of recipient cells, and significantly,
their ability to manipulate personalized medicine for some
diseases such as TBI. Exosomes can be operated ex vivo to
carry not only therapeutic drugs but also short interfering RNAs
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(siRNAs) targeted specific genes in the brain (van den Boorn
et al., 2011). One study indicated that exosomes generated from
self-derived dendritic cells inhibited target gene expression in
the brain via transporting siRNA to neurons, oligodendrocytes
and microglia, and that exosomes loaded with siRNAs could
be intravenous administrated and further silence the gene
expression in CNS (Alvarez-Erviti et al., 2011). Above studies
indicate that MSCs-derived exosomes can potentially act as a
non-invasive intervention for the transportation of therapeutic
agents into brain and further be applied in the treatment of TBI.
CONCLUSION AND FUTURE
PROSPECTS
Exosomes are the smallest EVs that contain proteins, lipids,
mRNAs and miRNAs and play an important role in the
cell–cell communications. MSCs-derived exosomes have many
advantages and promise to be a better therapeutic strategy for
TBI compared to MSCs. Newly studies indicate that MSCs-
derived exosomes improved functional recovery, promoted
neurogenesis and reduced neuroinflammation in rats after TBI.
Because the involved cellular and molecular mechanisms of
the effects produced by MSCs-derived exosomes in TBI are
unclear, some considerations are proposed in this review: (1)
The miRNAs might be potential research targets to explore
the reducing neuroinflammation and promoting neurogenesis
effects produced by MSCs-derived exosomes. (2) The neurogenic
niche might be a key research target to explore the promoting
neurogenesis effects produced by MSCs-derived exosomes.
Further, the combination of miRNAs and MSC-derived exosomes
might be a novel approach for the treatment of TBI and
MSC-derived exosomes have the potential to serve as a non-
invasive intervention for successful delivery of therapeutic
agents such as drugs and siRNAs to the brain and treat
TBI.
Although the results of previous proof-of-concept studies are
very encouraging, it is just a beginning for us to understand
the potential of MSCs-derived exosomes as a viable therapeutic
intervention for TBI. Several key points for the future exploration
of the implicit involved cellular and molecular mechanisms of
the effects produced by MSCs-derived exosomes in TBI and of
the development of MSC-derived exosomes to treat TBI should
be proposed, such as: (1) Alteration of exosomes cargos such
as miRNAs in the neurogenic niches of TBI animal model
and clinical patients, (2) Change of exosomes characteristics
and their cargos such as miRNAs in the cerebrospinal fluid
and peripheral blood of TBI model and patients, (3) Molecular
constituents included in MSCs-derived exosomes such as
miRNAs that promote angiogenesis and neurogenesis as well as
reduce neuroinflammation after TBI, (4) Available approaches
to engineer specific miRNAs into MSCs-derived exosomes, (5)
Precise percentage of MSCs-derived exosomes that cross the BBB
and finally reach the brain tissue, (6) Association between dose
and effect of MSCs-derived exosomes in TBI, (7) Construction of
standard MSCs source and culture conditions, (8) Exploration of
effective methods to isolate and identify MSCs-derived exosomes
from MSCs. Hence, much work should be conducted to take
full advantages of MSCs-derived exosomes and support their
potential to be a new strategy for the treatment of TBI in the
future. We envisage that many of this work will be addressed
by growing intense researches in the field of MSCs-derived
exosomes and TBI through a yet unsuspected manner.
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